RNAC Q3 2023 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-68.4% YoY

Gross Profit

-$6M-98.5% margin

Operating Income

-$13M-199.4% margin

Net Income

-$9M-137.4% margin

EPS (Diluted)

$-1.74

QoQ Revenue Growth

+24.8%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$106M

Total Liabilities

$46M

Stockholders' Equity

$60M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$21M	-68.4%
Gross Profit	-$6M	$20M	-132.0%
Operating Income	-$13M	-$2M	-717.1%
Net Income	-$9M	-$8M	-14.1%